Call 413.540.1234 to
schedule an appointment
CONCERN/EAP: 413.534.2625
Billing questions? Call: 413.540.1212
CRISIS: 413.733.6661

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Doubts Raised About Use of Products Containing OxybenzoneReport: Industry Hid Decades-Old Study Showing Sugar's Unhealthy EffectsMany Health Care Providers Work While SickMore Patients Are Having a Say in Their Medical CareFDA Seeks to Speed Development of 'Regenerated' Organs for Medical UseHealth Care Experts in Favor of Patient Contribution to NotesMillions Could Miss Out on a Potential Alzheimer's BreakthroughU.S. May Still Benefit From Climate AccordHealth Tip: Spread Awareness of the Opioid EpidemicKnowing Too Much About Your Genes Might Be RiskyHealth Tip: Participating in a Clinical TrialMusic, Video Help Sixth-Graders Master Hands-Only CPRIncreases in U.S. Health Spending Tied to Health Service PriceHealth Tip: Prevent Germs at the Doctor's OfficeInfo Via Social Media Apps May Increase Vaccine AcceptanceIt's 'Buyer Beware' When Purchasing Medical Pot Extract OnlineGetting Self-Driving Cars on the Road Soon Might Save LivesHealth Tip: Defining Health LiteracyDoctor Burnout: A Big Health Threat in U.S.About Half of Americans Get Health Care in ERPricing Interventions Increase Sales, Intake of Healthy FoodsHealth Tip: Get to Know Your PharmacistRobots May Be Cleaning Your Hospital Room SoonCMS Launches Initiative to Examine Impact of RegulationsPatients Prefer Face-to-Face Communication, No ComputerDrop Off Your Unused Meds Saturday on 'Take Back Day'Concerns Surround Use of Direct-to-Consumer Genetic TestingMost Patients Satisfied With Relationship With PhysicianModule Developed to Improve Adult Vaccination RatesA Drug Company's Gift Might Change How Your Doctor PrescribesAlmost 4 in 10 Tanning Salons Flout State LawsDEA Taking Back Unwanted Prescription Drugs on Oct. 28Most in U.S. Don't Agree That Household Guns Up Suicide RiskCan Gun Shows Trigger Gun Violence?Tighter Rules on Arsenic in Water Saved Lives: StudyHerbal and Dietary Supplements Are Commonly Mislabeled3 Million Americans Say They Carry Handguns Every DayMany Dermatology Guideline Authors Get Industry PaymentsDoctors Urged to Speak With Patients About FirearmsStates That Make You Wait to Buy Guns Have Fewer Deaths: StudyHomicides Devastate Black Communities, But Prevention Gets Little FundingBetter Patient Communication Needed After Urgent CareQuality Issues for Both Paper-, Electronic-Based Health RecordsRide-Sharing Services Could Cut Alcohol-Related CrashesLow-Cost Services a Major Player in Unnecessary Health SpendingMedical License Questions Sway Doctors' Mental Health Help'Heat-Not-Burn Cigarettes' Aiming for U.S. MarketInjured Patients Want More Info on Safety Improvement EffortsFDA Approves Test to Screen Donated Blood for Zika21 Percent of Americans Report Experiencing a Medical Error
Questions and AnswersLinksBook Reviews
Related Topics

Median Cost of Cancer Drug Development $648.0 Million


HealthDay News
Updated: Sep 11th 2017

new article illustration

MONDAY, Sept. 11, 2017 (HealthDay News) -- The median cost of cancer drug development is $648.0 million, and revenue after approval is substantial, according to a study published online Sept. 11 in JAMA Internal Medicine.

Vinay Prasad, M.D., M.P.H., from the Oregon Health and Science University in Portland, and Sham Mailankody, M.B.B.S., from the Memorial Sloan Kettering Cancer Center in New York City, estimated cumulative research and development (R&D) spending from initiation of drug development activity to date of approval for cancer drugs. The analysis included 10 companies and drugs.

The researchers found that the median time to develop a drug was 7.3 years for the 10 companies. Five of the drugs received accelerated approval from the U.S. Food and Drug Administration, and five received regular approval. Drug development cost a median of $648.0 million. The median cost was $757.4 million and $793.6 million for a 7 percent per annum cost of capital and for a 9 percent opportunity costs, respectively. The total revenue from sales of these 10 drugs was $67.0 billion with a median of 4.0 years since approval, compared with $7.2 billion in total R&D spending.

"The cost to develop a cancer drug is $648.0 million, a figure significantly lower than prior estimates," the authors write. "This analysis provides a transparent estimate of R&D spending on cancer drugs and has implications for the current debate on drug pricing."

One author disclosed financial ties to the biopharmaceutical industry; the second received fees for speaking at conferences in the health care industry.

Abstract/Full Text
Editorial